Search
for
Sort by
Research 211–240 of 1000+
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Hydroxychloroquine modulates the progression of experimentally induced benign prostatic hyperplasia in rats via targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways: computational and in vivo studies
- MiRNA-24 downregulates KLF6 affecting STAT3 protein expression and phosphorylation regulating melanogenesis in cashmere goat coat
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Effect of diode pumping solid state laser with wavelength 589 nm on gene expression of interlukine-2 and interferon-gamma Lowercase in human T-lymphocytes
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- JAK inhibitors in dermatology: The promise of a new drug class
- JAK inhibition decreases the autoimmune burden in Down syndrome
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Janus Kinase inhibitors in dermatology: a review
- ROS-responsive hydrogel-delivered miR-665 targets STAT3 to alleviate inflammation and promote hair follicle regeneration in alopecia areata
- ROS-responsive hydrogel-delivered miR-665 targets STAT3 to alleviate inflammation and promote hair follicle regeneration in alopecia areata
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment
- Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Immune cell regulation of the hair cycle
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- JAK Inhibitors for Treatment of Alopecia Areata
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies